Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats

Journal of the American Society of Nephrology

Volumn 11, Issue 8, 2000, Pages 1469-1478

  Amann, Kerstin ^d   Rump, Lars Christian ^c   Simonaviciene, Aurelia ^c   Oberhauser, Vitus ^c   Wessels, Sabine ^c   Orth, Stephan R ^c   Gross, Marie Luise ^c   Koch, Andreas ^c   Bielenberg, Gerhard W ^a   Van Kats, Jorge P ^b   Ehmke, Heimo ^c   Mall, Gerhard ^c   Ritz, Eberhard ^c  

^a Solvay Pharmaceuticals GmbH   (Germany)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c Department of Pathology ^*

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN; MOXONIDINE; NORADRENALIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GEOMETRY; GLOMERULOSCLEROSIS; IMMUNOHISTOCHEMISTRY; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; SYMPATHETIC BLOCKING; URINARY EXCRETION;

EID: 0033912730     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v1181469     Document Type: Article

References (49)

1. Brenner BM: Nephron adaptation to renal injury or ablation. Am J Physiol 249: F324-F337, 1985
2. Ibrahim HN, Rosenberg ME, Hostetter TH: Role of the renin-angiotensin-aldosterone system in the progression of renal disease: A critical review. Semin Nephrol 17: 431-440, 1997
3. DiBona GF: Neural control of renal function: Cardiovascular implications. Hypertension 4: 753-763, 1982
4. Campese VM, Kogosov E, Koss M: Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 26: 861-865, 1995
5. Campese VM, Kogosov E: Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 25: 878-882, 1995
6. Hansen J, Victor RG: Direct measurement of sympathie activity: New insights into disordered blood pressure regulation in chronic renal failure. Curr Opin Nephrol Hypertens 3: 636-643, 1994
7. Converse RL, Jacobsen TN, Toto RD, Jost CMT, Cosentino F, Fouad-Tarazi F, Victor RG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327: 1912-1918, 1992
8. Miltenberger-Miltenyi G, Schwarz U, Amann K, Mall G, Ritz E: Beneficial effect of low-dose treatment with a combination of moxonidine and nifedipine on glomerulosclerosis in experimental hypertension. Blood Pressure 9: P247, 1998
9. 3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 53: 1696-1705, 1998
10. Amann K, Kronenberg G, Gehlen F, Orth SR, Munter K, Ehmke H, Mall G, Ritz E: Cardiac remodeling in experimental renal failure: An immunohistochemical study. Nephrol Dial Transplant 13: 1958-1966, 1998
11. Brockway BP, Mills PA, Aszar SH: A new method for continuous chronic measurement and recording of blood pressure, heart rate and activity in the rat via radiotelemetry. Clin Exp Hypertens 13: 885-895, 1991
12. Amann K, Irzyniec T, Mall G, Ritz E: The effect of enalapril on glomerular growth and glomerular lesions after subtotal nephrectomy: A stereological study. J Hypertension 11: 969-975, 1993
13. Weibel ER: Practical methods of biological morphometry. In: Stereological Methods, New York, Academic Press, 1979
14. Nabokov A, Amann K, Wagner J, Gehlen F, Munter K, Ritz E: Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nephrol Dial Transplant 11: 514-520, 1996
15. van Kats JP, de Lannoy LM, Danser AHJ, van Meegen JR, Verdouw PD, Schalekamp MADH: Angiotensin II type I (ATI) receptor mediated accumulation of angiotensin II in tissues and its intracellular half life in vivo. Hypertension 30: 42-49, 1997
16. van Kats JP, Danser AHJ, van Meegen JR, Sassen LMA, Verdouw PD, Schalekamp MADH: Angiotensin production by the heart: A quantitative study in pigs with the use of radiolabeled angiotensin infusion. Circulation 98: 73-81, 1998
17. Rump LC, Schuster MJ, Schollmeyer P: Activation of β2-adrenoceptors by isoprenaline and adrenaline enhances noradrenaline release in cortical kidney slices of young spontaneously hypertensive rats. Naunyn-Schmiedebergs Arch Pharmacol 345: 25-32, 1992
18. Rump LC, Wilde K, Bohmann C, Schollmeyer P: Effects of the novel dopamine DA2-receptor agonist carmoxirole (EMD 45609) on noradrenergic and purinergic neurotransmission in rat isolated kidney. Naunyn-Schmiedebergs Arch Pharmacol 345: 300-308, 1992
19. Bohmann C, Kügelgen I, Rump LC: P2-receptor modulation of noradrenergic neurotransmission in rat kidney. Br J Pharmacol 121: 1255-1262, 1997
20. 1,-Imidazoline agonist moxonidine decreases sympathie nerve activity and blood pressure in hypertensives. Hypertension 32: 1022-1027, 1998
21. Bohmann C, Schollmeyer P, Rump LC: Effects of imidazolines on noradrenaline release in rat isolated kidney. Naunyn-Schmiedebergs Arch Pharmacol 349: 118-124, 1994
22. + exchange in proximal tubule cells and cortical collecting duct. Kidney Int 52: 454-459, 1997
23. Smyth DD, Penner SB: Imidazoline receptor mediated natriuresis: Central and/or peripheral effect? J Auton Nerv Syst 72: 155-162, 1998
24. Beierwaltes WH, Schryver S, Olson PS, Romero JC: Control of renin release in isolated rat glomeruli. Hypertension 3: II30-II34, 1981
25. Johns EJ: Role of angiotensin II and the sympathetic nervous system in the control of renal function. J Hypertension 7: 695-701, 1989
26. Ligtenberg G, Blankestijn J, Oey L, Klein IHH, Dijkhorst-Oei L-T, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA: Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340: 1321-1328, 1999
27. Navar LG, Imig JD, Zou L, Wang CT: Intrarenal production of angiotensin II. Semin Nephrol 17: 412-422, 1997
28. Wolf G, Helmchen U, Stahl RAK: Isoproterenol stimulates tubular DNA replication in mice. Nephrol Dial Transplant 11: 2288-2292, 1996
29. Kriz W, Gretz N, Lemley KV: Progression of glomerular diseases: Is the podocyte the culprit? Kidney Int 54: 687-697, 1998
30. Huber TB, Gloy J, Henger A, Schollmeyer P, Greger R, Mundel P, Pavenstädt H: Catecholamines modulate podocyte function. J Am Soc Nephrol 9: 335-345, 1998
31. Hermansson K, Larson M, Kallskog O, Wolgast M: Influence of renal nerve activity on arteriolar resistance, ultrafiltration dynamics and fluid reabsorbtion. Pflügers Arch 389: 85-90, 1981
32. Kon V, Karnovsky MJ: Morphologic demonstration of adrenergic influences on the glomerulus. Am J Pathol 134: 1039-1046, 1989
33. Pavenstädt H: New aspects concerning the role of the catecholamines in the pathogenesis of glomerular disease. Nephrol Dial Transplant 13: 1916-1919, 1998
34. Amann K, Nichols C, Törnig J, Schwarz U, Zeier M, Mall G, Ritz E: Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 11: 1003-1011, 1996
35. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998
36. Mühlbauer B, Spöhr F, Schmidt R, Osswald H: Role of renal nerves and endogenous dopamine in amino acid-induced glomerular hyperfiltration. Am J Physiol 273: F144-F149, 1997
37. Ye S, Ozgur B, Campese VM: Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 51: 722-727, 1997
38. Ye S, Nosrati S, Campese VM: Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure (CRF). J Clin Invest 99: 540-548, 1997
39. Saruta T, Kumgai H: The sympathetic nervous system in hypertension and renal disease. Curr Opin Nephrol Hypertens 5: 72-70, 1998
40. Haynes WG, Morgan DA, Djalali A, Sivitz WI, Mark AL: Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension 33: 542-547, 1999
41. 2D-Adrenoceptors modulate renal norepinephrine release in normotensive and spontaneously hypertensive rats. Eur J Pharmacol 271: 283-292, 1994
42. Bohmann C, Rist W, Schollmeyer P, Rump LC: Low concentrations of angiotensin II unmask vasoconstrictory α-2-adrenoceptors in isolated perfused kidneys of spontaneously hypertensive rats. Cardiovasc Res 30: 857-865, 1995
43. Oberhauser V, Vonend O, Rump LC: Neuropeptide Y and ATP interact to control renovascular resistance in the rat. J Am Soc Nephrol 10: 1179-1185, 1999
44. Bohmann C, Schollmeyer P, Rump LC: α-Autoreceptor subclassification in rat isolated kidney by use of short trains of electrical stimulation. Br J Pharmacol 108: 262-268, 1993
45. 2-receptor activation inhibits noradrenaline release in human kidney slices. Kidney Int 43: 197-204, 1993
46. Bald M, Gerigk M, Rascher W: Elevated plasma concentrations of neuropeptide in children and adults with chronic and terminal renal failure. Am J Kidney Dis 30: 23-27, 1997
47. +-ATPase activity. Kidney Int 45: 1606-1613, 1994
48. Weinrauch LA, Kennedy FP, Gleason RE, Keough J, D'Elia JA: Relationship between autonomic function and progression of renal disease in diabetic proteinuria. Am J Hypertens 11: 302-308, 1998
49. Benigni A, Remuzzi G: Mechanism of progression of renal disease: Growth factors and related mechanisms. J Hypertens 16: 9-12, 1998